Robert Pierce
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Robert Pierce
Faeth Therapeutics, Inc. reported in an 8-K filed December 8, 2022 that Robert Pierce was terminated as Chief Research and Development Officer, effective December 7, 2022. The proxy statement of Faeth Therapeutics, Inc. reports total compensation of $1,187,277 for Robert Pierce in fiscal 2022, including a base salary of $421,154. Disclosed compensation is on record for 2 fiscal years.
“On December 7, 2022, the Company notified Robert Pierce, who had been serving as the Company's Chief Research and Development Officer, that his employment with the Company would terminate, effective December 7, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Faeth Therapeutics, Inc. (FTH)
Proxy statement
Start not stated–2022-12-07
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Faeth Therapeutics, Inc. (FTH) | Former Chief R&D Officer | $421,154 | $1,187,277 |
| 2021 | Faeth Therapeutics, Inc. (FTH) | Former Chief R&D Officer | $410,000 | $2,261,413 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.